The historical rank and industry rank for Strata Skin Sciences's FCF Margin % or its related term are showing as below:
FRA:E2O'
s FCF Margin % Range Over the Past 10 Years
Min: -16.6 Med: -3.27 Max: 6.55
Current: -13.87
During the past 13 years, the highest FCF Margin % of Strata Skin Sciences was 6.55%. The lowest was -16.60%. And the median was -3.27%.
FRA:E2O's FCF Margin % is ranked worse than 68.22% of 815
companies
in the Medical Devices & Instruments industry
Industry Median: -0.03
vs FRA:E2O: -13.87
Strata Skin Sciences FCF Margin % Related Terms
Strata Skin Sciences FCF Margin % Historical Data
* Premium members only.
The historical data trend for Strata Skin Sciences's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:E2O vs IRME, NUMD, WOK: FCF Margin % Comparison
For the Medical Devices subindustry, Strata Skin Sciences's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Strata Skin Sciences FCF Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Strata Skin Sciences's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Strata Skin Sciences's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Strata Skin Sciences (FRA:E2O) has a FCF Margin % of -5.92% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Strata Skin Sciences and its competitors. According to the industry distribution chart, Strata Skin Sciences ranks #556 out of 815 companies in the Medical Devices & Instruments industry, placing it in the top 68.2%.
Is Strata Skin Sciences' FCF Margin % too high?
Strata Skin Sciences' current FCF Margin % is -5.92%. Based on the distribution chart, Strata Skin Sciences ranks #556 out of 815 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Strata Skin Sciences has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does Strata Skin Sciences' FCF Margin % compare to IRME and NUMD?
According to the Medical Devices & Instruments industry distribution chart, Strata Skin Sciences ranks #556 out of 815 companies for FCF Margin %. This places Strata Skin Sciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Devices & Instruments company?
A good FCF Margin % depends on the Medical Devices & Instruments industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Strata Skin Sciences and its competitors. Strata Skin Sciences's current FCF Margin % is -5.92%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Strata Skin Sciences stock overvalued right now?
Strata Skin Sciences (FRA:E2O) has a current FCF Margin % of -5.92%. The stock's GF Value™ is €58.84, compared to a current price of €3.76 — trading 93.6% below its estimated fair value. The current FCF Margin % is -5.92%. Strata Skin Sciences' overall GF Score™ is 38/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Strata Skin Sciences (FRA:E2O), the current FCF Margin % is -5.92% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Strata Skin Sciences (FRA:E2O) Overvalued in 2026?
Based on GuruFocus' analysis, Strata Skin Sciences stock appears to be undervalued.
The current stock price of €3.76 is trading 93.6% below its estimated GF Value™ of €58.84.
Key valuation signals for FRA:E2O:
FCF Margin %: -5.92%
GF Value™: €58.84 vs. price of €3.76 (93.6% below fair value)
No single metric tells the full story. See the FRA:E2O stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Strata Skin Sciences Inc is a medical technology company engaged in developing and commercializing products for the treatment of dermatological disorders. Its primary products include the XTRAC excimer laser and VTRAC lamp systems utilized in the treatment of psoriasis, vitiligo, and various other skin conditions. Its operating segment includes Dermatology Recurring Procedures, which is the key revenue driver, and Dermatology Procedures Equipment. The Dermatology Recurring Procedures segment derives its revenues from the usage of its equipment by dermatologists to perform XTRAC procedures. Its Dermatology Procedures Equipment segment generates revenues from the sale of equipment, such as lasers and lamp products. Geographically, it derives a majority of revenue from the United States.
38GF Score
Get the complete analysis for FRA:E2O
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:E2O has been successfully added to your 
